Poor
Not Aligned
Patient Risk:
High
Summary
The response contains many substantive heart-failure claims, contraindication/monitoring statements, and dosing-context statements that are not supported by the provided label excerpts (which only include pregnancy/fetal toxicity text). Only pregnancy/fetal harm content is demonstrably supported by the supplied prescribing information.
Category Scores
Accurate Statements
Sacubitril and valsartan tablets can cause fetal harm when administered to a pregnant woman; use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death; when pregnancy is detected, consider alternative treatment and discontinue sacubitril/valsartan (with a lifesaving exception if no alternative).
Supported by provided label excerpts in Warnings and Precautions (5.1 Fetal Toxicity) and Use in Specific Populations (8.1 Pregnancy).
Unsupported Statements
Sacubitril/valsartan is used to treat certain types of heart failure.
Not supported by the provided label excerpts (only pregnancy/fetal toxicity text was supplied).
Sacubitril/valsartan helps the heart work more efficiently.
Not supported by the provided label excerpts.
Sacubitril/valsartan can reduce hospitalizations.
Not supported by the provided label excerpts.
Sacubitril/valsartan is commonly prescribed for chronic (long-term) heart failure with reduced ejection fraction (HFrEF).
Not supported by the provided label excerpts.
Sacubitril/valsartan is used in some cases for heart failure with mildly reduced or preserved ejection fraction depending on local guidelines and the patient’s clinical profile.
Not supported by the provided label excerpts.
Sacubitril helps increase natriuretic peptides by inhibiting neprilysin.
Not supported by the provided label excerpts.
Sacubitril supports vasodilation.
Not supported by the provided label excerpts.
Sacubitril helps reduce fluid retention.
Not supported by the provided label excerpts.
Valsartan is an angiotensin receptor blocker (ARB).
Not supported by the provided label excerpts.
Valsartan lowers the effects of angiotensin II.
Not supported by the provided label excerpts.
Valsartan reduces strain on the cardiovascular system.
Not supported by the provided label excerpts.
Sacubitril/valsartan improves symptoms and functional status in appropriate heart failure patients.
Not supported by the provided label excerpts.
Sacubitril/valsartan reduces the risk of heart-failure-related hospitalization.
Not supported by the provided label excerpts.
Sacubitril/valsartan lowers the risk of death in eligible patients with HFrEF.
Not supported by the provided label excerpts.
A key contraindication is taking sacubitril/valsartan with medicines that include neprilysin inhibition.
Not supported by the provided label excerpts (no contraindications section supplied).
Sacubitril/valsartan must not be started within the required washout window after stopping medicines that include neprilysin inhibition.
Not supported by the provided label excerpts (no contraindications/washout language supplied).
Patients are evaluated for kidney function before and during treatment with sacubitril/valsartan.
Not supported by the provided label excerpts (no monitoring section supplied).
Patients are evaluated for blood pressure before and during treatment with sacubitril/valsartan.
Not supported by the provided label excerpts.
Patients are evaluated for potassium levels before and during treatment with sacubitril/valsartan.
Not supported by the provided label excerpts.
Monitoring includes blood pressure to avoid hypotension.
Not supported by the provided label excerpts.
Monitoring includes kidney function (serum creatinine/eGFR).
Not supported by the provided label excerpts.
Monitoring includes potassium levels to watch for hyperkalemia.
Not supported by the provided label excerpts.
Sacubitril/valsartan is commonly used alongside other standard heart failure therapies.
Not supported by the provided label excerpts.
The exact combination of sacubitril/valsartan with other heart failure medicines depends on blood pressure, kidney function, potassium, and how the patient tolerates each medicine.
Not supported by the provided label excerpts.
Sacubitril/valsartan is commonly prescribed for chronic (long-term) heart failure with reduced ejection fraction (HFrEF).
Not supported by the provided label excerpts.
Contradictions
Important Omissions
The response does not explicitly reproduce or discuss the label’s fetal/neonatal adverse reaction specifics in pregnancy (e.g., oligohydramnios leading to reduced fetal renal function, anuria/renal failure, lung hypoplasia, skeletal deformities, hypotension, death) or the label guidance to perform serial ultrasound examinations and closely observe neonates for hypotension, oliguria, and hyperkalemia after in utero exposure.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many major clinical claims (indication, efficacy outcomes, contraindication/washout details, and monitoring instructions) are not supported by the supplied label excerpts; only pregnancy/fetal harm language is clearly supported. This limits the ability to ensure on-label accuracy for safety-critical areas beyond pregnancy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are not verifiable against the provided FDA label excerpts, which contain only pregnancy/fetal toxicity information; contraindication and monitoring claims are especially unsupported.
Suggested Improvement
Restrict claims to the provided label content (fetal toxicity/pregnancy counseling) and, for other sections (indications, contraindications/washout, dosing, monitoring, adverse reactions), use the corresponding label text excerpts.